Travere Therapeutics (TVTX) CEO trades shares after PSU performance vesting

Rhea-AI Filing Summary

Travere Therapeutics CEO Eric M. Dube exercised performance-based restricted stock units and sold shares in a planned, routine transaction. On May 6, 2026, he sold 22,500 shares of common stock at $43.95 per share in an open-market trade under a pre-arranged Rule 10b5-1(c) plan that also covered tax obligations from vesting.

Two days earlier, on May 4, 2026, he exercised 22,500 performance-based restricted stock units into common shares and received a new grant covering 45,000 PSUs. The filing states 50% of these PSUs vested after a cumulative FILSPARI net revenue performance target was confirmed, with an additional 25% scheduled to vest on January 31, 2027 if he remains in continuous service.

After these transactions, Dube directly holds 432,886 shares of Travere Therapeutics common stock, indicating he retains a substantial equity stake.

Insider Trade Summary 10b5-1

Net Seller: 22,500 shares ($988,875)

Net Sell 4 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 22,500 shs ($989K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,500	$43.95	$989K
Grant/Award	Performance-based restricted stock units	45,000	$0.00	--
Exercise	Performance-based restricted stock units	22,500	$0.00	--
Exercise	Common Stock	22,500	$0.00	--

Holdings After Transaction: Common Stock — 432,886 shares (Direct, null); Performance-based restricted stock units — 45,000 shares (Direct, null)

Footnotes (1)

1. On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

Key Figures

Shares sold: 22,500 shares Sale price: $43.95 per share Shares held after sale: 432,886 shares +3 more

6 metrics

Shares sold 22,500 shares Open-market sale on May 6, 2026

Sale price $43.95 per share Price for 22,500 sold shares

Shares held after sale 432,886 shares Direct ownership after transactions

PSUs exercised 22,500 units Performance-based RSUs converted on May 4, 2026

New PSU grant size 45,000 units Performance restricted stock units granted January 31, 2024

Future vesting portion 25% of PSUs To vest January 31, 2027 with continuous service

Key Terms

performance restricted stock units, Rule 10b5-1(c), cumulative FILSPARI net revenue, contingent right

4 terms

performance restricted stock units financial

"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares"

Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.

Rule 10b5-1(c) regulatory

"This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

cumulative FILSPARI net revenue financial

"a performance criterion related to cumulative FILSPARI net revenue had been achieved"

contingent right financial

"Each PSU represents a contingent right to receive one share of the Issuer's common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		M(1)		22,500	A	$0	455,386	D
Common Stock	05/06/2026		S(2)		22,500	D	$43.95	432,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-based restricted stock units	(3)	05/04/2026		A(1)		45,000		(1)	(1)	Common Stock	45,000	$0	45,000	D
Performance-based restricted stock units	(3)	05/04/2026		M(1)			22,500	(1)	(1)	Common Stock	22,500	$0	22,500	D

Explanation of Responses:

1. On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

2. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

3. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Travere Therapeutics (TVTX) CEO Eric M. Dube do in this Form 4 filing?

Eric M. Dube reported exercising performance-based restricted stock units and selling shares. He exercised 22,500 PSUs into common stock, then sold 22,500 shares at $43.95 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan.

How many Travere Therapeutics (TVTX) shares did the CEO sell and at what price?

The CEO sold 22,500 shares of Travere Therapeutics common stock. The open-market sale occurred at a price of $43.95 per share on May 6, 2026, as disclosed in the Form 4 insider transaction report for Eric M. Dube.

How many Travere Therapeutics (TVTX) shares does the CEO hold after these transactions?

Following the reported transactions, CEO Eric M. Dube directly holds 432,886 shares of Travere Therapeutics common stock. This post-transaction holding figure comes from the Form 4 and shows his remaining equity position after the exercise and sale activity.

What performance-based restricted stock units (PSUs) were involved for Travere Therapeutics (TVTX) CEO?

Dube was granted 45,000 PSUs on January 31, 2024, tied to performance milestones. On May 4, 2026, 50% vested after confirmation that a cumulative FILSPARI net revenue target was achieved, resulting in 22,500 shares converting into common stock.

What future vesting is expected from the CEO’s Travere Therapeutics (TVTX) PSU grant?

The filing states that, contingent on continuous service by Eric M. Dube, an additional 25% of the performance-based restricted stock units will vest on January 31, 2027. This future vesting relates to the timing of achieving the cumulative FILSPARI net revenue performance criterion.

Was the Travere Therapeutics (TVTX) CEO sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements. The plan also covered selling shares to satisfy tax obligations triggered by PSU vesting.